Russian courts have clarified SAR redomiciliation and pharma sector licensing. Key implications for foreign-held structures in Russia. Make an enquiry.
In a decision handed down in the course of 2027, a Russian arbitrazh court addressed a question that has been live for several years among foreign holding structures with Russian pharmaceutical assets: whether a company that has redomiciled to one of Russia's two Special Administrative Regions (SARs) — Russky Island in Primorsky Krai or Oktyabrsky Island in Kaliningrad Oblast — retains the benefit of SAR residency status when the principal activity of the Russian operating subsidiary falls under the pharmaceutical licensing regime administered by Roszdravnadzor. The decision matters not because it resolves every ambiguity in the SAR framework, but because it marks the first time a court has directly engaged with the intersection of SAR corporate law and sector-specific regulatory approval — an intersection that private wealth structures with diversified Russian portfolios can no longer treat as a theoretical concern.
Russia's SAR framework was introduced to offer a domestic alternative to traditional offshore holding jurisdictions. Two territories — Russky Island and Oktyabrsky Island — were designated as the sites for this experiment in onshore preferential treatment, with the regime designed to attract foreign holding companies to redomicile under Russian corporate law whilst retaining selected fiscal and currency-control advantages. For families and private investors holding Russian productive assets through offshore intermediaries, the SAR offered something genuinely useful: a path to normalise a cross-border structure without fully dismantling it, and to access dividend relief and IP box concessions within a recognisable legal framework.
The pharmaceutical sector adds a layer that the SAR legislation did not address expressly. In Russia, the production, distribution, import, and clinical development of pharmaceutical products are all subject to mandatory licences issued by or under the supervision of the Federal Service for Healthcare Surveillance (Roszdravnadzor) and, for certain product categories, the Ministry of Health. These licences attach to the Russian operating entity — not to the holding company, whether SAR-resident or otherwise. The structural question that the case brought into relief was whether a SAR-resident holding company that exercises active governance over a licensed pharmaceutical subsidiary is thereby engaged in "regulated activity" in a manner that triggers additional compliance obligations under the SAR residency conditions — or whether the holding function remains, as a matter of Russian administrative law, categorically distinct from the licensed operational activity.
The proceedings arose following a regulatory review initiated by the relevant administrative authority into the activities of a SAR-resident international holding company whose Russian operating subsidiary held pharmaceutical production and import licences. The authority's position was that the holding company's structural oversight of the subsidiary's licensed activities — including approval of regulated contracts and participation in compliance governance — brought it within the scope of the pharmaceutical regulatory regime in a manner inconsistent with unconditioned SAR residency benefits.
The arbitrazh court declined to sustain the authority's characterisation. It held, in substance, that SAR residency status is defined by the corporate law conditions set out in the SAR legislation and the company's registered status with the relevant SAR management company, not by the downstream regulatory classification of the Russian operating entities whose shares it holds. The court drew a careful distinction between governance participation — which a holding company by definition exercises — and the conduct of licensed pharmaceutical activity, which requires a specific operational nexus: physical presence in the regulated process, direct employment of licensed personnel, and material involvement in production or import decisions at the operational level.
"The decision correctly preserves the structural logic of the SAR framework: a holding company does not become a pharmaceutical operator merely because its subsidiary is one." — Elizaveta Razina, Senior Lawyer, Practice Lead — IP Enforcement, Vetrov & Partners
The court's reasoning is notable for what it affirms rather than what it creates. It draws on established administrative law principles that distinguish between the holder of a licence and the owner of the entity that holds the licence — a distinction familiar to any practitioner who has advised on pharmaceutical M&A in Russia, but one that had not previously been applied in the SAR context. The ruling does not provide absolute insulation: the court's analysis leaves open the question of whether a SAR-resident holding company that provides management services to a regulated subsidiary under a formal services agreement, and charges a fee for doing so, might be characterised differently. That question remains unresolved as a matter of first-instance jurisprudence and represents the most significant residual uncertainty for structuring purposes.
If your private structure includes SAR-resident holdings with regulated Russian subsidiaries, a review of the governance arrangements in light of this decision is prudent — discuss your matter in confidence: info@vetrovpartners.com |
For advisers to family offices and private investors whose Russian portfolio includes pharmaceutical assets, the immediate implication is calibrated relief rather than a clean bill of health. The court has confirmed that passive holding of a licensed pharmaceutical subsidiary does not, by itself, disqualify a company from SAR residency benefits — a position that the Ministry of Finance guidance on special administrative regions had suggested but not definitively established. That guidance can now be read alongside this decision as a complementary signal that the Russian state intends to preserve SAR utility for holding structures in regulated sectors, provided the holding company remains structurally distinct from the operational layer.
The more significant implication concerns governance design. Families and investment offices that have migrated, or are considering migrating, to the SAR framework for their Russian pharmaceutical interests should examine the precise scope of the holding company's involvement in subsidiary-level decisions. Board representation, veto rights over regulated contracts, and participation in Roszdravnadzor compliance procedures are all areas where the line between governance and participation in regulated activity could be argued. The decision provides a defensible framework, but it does not eliminate the need for a contemporaneous legal opinion on the specific structural arrangements in place.
Practitioners advising on initial SAR redomiciliation in the pharmaceutical sector — an exercise considered in more detail in our overview of Special Administrative Regions in Russia — should also note that the court's analysis was confined to an existing SAR-resident structure. Companies in the process of redomiciling should obtain specific advice on whether the governance arrangements being put in place at the point of redomiciliation are consistent with the court's framework, rather than retrofitting a governance review after the fact. Earlier action preserves the full range of structural options.
Our Private Wealth & Asset Protection practice advises foreign families and their advisers on the design and maintenance of Russian holding structures, including SAR redomiciliation and the management of regulatory interface risks in sectors subject to licensing. For matters requiring cross-border coordination, we collaborate with trusted counsel in the relevant jurisdiction. A record of representative matters is available at /matters/.
To discuss the implications of this decision for a specific pharmaceutical holding structure — make an enquiry: info@vetrovpartners.com |
Q: What does this ruling change?
A: The ruling clarifies that a SAR-resident holding company does not lose its registered status or the associated preferential conditions merely because its Russian operating subsidiary holds pharmaceutical licences issued by Roszdravnadzor or the Ministry of Health. The court confirmed that SAR residency is a corporate law status determined by the conditions of the SAR framework itself, not by the regulatory classification of downstream subsidiaries. The practical effect is that advisers can proceed on the basis that passive holding of a licensed pharmaceutical business is compatible with SAR residency — subject to the ongoing caveat that the holding company must not conduct regulated pharmaceutical activity directly and that management services agreements between holding and operating entities may require careful structuring.
Q: What should foreign companies do in light of this decision?
A: Foreign families and holding structures with SAR-resident companies above Russian pharmaceutical assets should undertake a governance review to confirm that the holding company's involvement in subsidiary-level decisions falls within the boundaries the court has affirmed. In particular, any formal management services agreement between the holding company and the licensed subsidiary should be reviewed against the court's reasoning. Structures that are in the process of redomiciling to a SAR should obtain advice before completing the transfer, so that the governance design is tested from the outset rather than corrected retrospectively. The Private Wealth & Asset Protection practice at Vetrov & Partners is available to advise on both existing structures and new redomiciliation exercises.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry